This week (February 21 to February 25), the medical device sector fluctuated greatly. Affected by the fluctuation of epidemic situation in duonei and other places, the concept of anti epidemic continued to rise in the first half of the week. On February 24, due to the influence of the international situation, A-Shares suffered a short-term heavy blow. However, due to no substantive action from the US and Europe, A-Shares began to recover gradually. As of the closing of the 25th, the medical sector ushered in a sharp rise, the cro concept, medical devices, medical beauty and other branches strengthened across the board, and the covid-19 detection and covid-19 treatment sector rose sharply. It is worth noting that Andon Health Co.Ltd(002432) opened high and went low this week. After the span of limit rise and limit fall, the final weekly increase was fixed at 0.53%.
In the top 10 list of market value of A-share medical device industry, only three shares in this week’s list fell, while the rest rose. In terms of circulation market value, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Shanghai Pharmaceuticals Holding Co.Ltd(601607) market value fell, and the market value of the other eight companies increased to varying degrees. The specific ranking performance has no significant change compared with last week. Only Suzhou Ta&A Ultra Clean Technology Co.Ltd(300390) and Shanghai Pharmaceuticals Holding Co.Ltd(601607) rank swap, of which Boe Technology Group Co.Ltd(000725) market value increased by 10.021 billion yuan, becoming the enterprise with the largest market value increase and the enterprise with the largest market value evaporation was 2.112 billion yuan of Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) .
In terms of news, on February 21, according to the official website of the State Food and drug administration, Li Li, Secretary of the Party group of the State Food and drug administration, stressed during his visit to the drug evaluation center that he would coordinate the drug evaluation and the construction of a clean and honest government. Li Li pointed out that we should adhere to early intervention, research and review linkage, be scientific and rigorous, comply with laws and regulations, and go all out to promote the listing of covid-19 products.
Affected by this news, A-share covid-19 concept stocks rose again, including covid-19 treatment, covid-19 drugs, traditional Chinese medicine, medical devices, covid-19 detection, masks, disinfectants, biological vaccines, etc. As of press time, Guangzhou Kingmed Diagnostics Group Co.Ltd(603882) , Guangzhou Wondfo Biotech Co.Ltd(300482) , Chengda pharmaceutical and anxiu biology have risen the limit, Aba Chemicals Corporation(300261) , Hybio Pharmaceutical Co.Ltd(300199) , Youcare Pharmaceutical Group Co.Ltd(688658) , Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) and other stocks have led the rise.
In this regard, Sinolink Securities Co.Ltd(600109) believes that the normalization of the epidemic situation and the expectation of influenza are optimistic about the oral covid-19 drugs and the large amount of in vitro testing. AVIC Securities believes that in the short to medium term, the global spread of the epidemic is still severe. With paxlovid approved for emergency listing in China, it is suggested to continue to pay attention to the investment opportunities of covid-19 small molecule drug industry chain and the listed companies deeply involved in covid-19 prevention and control supply chain.
In terms of individual stocks, Guangzhou Kingmed Diagnostics Group Co.Ltd(603882) opened at 79.18 yuan on February 25. As of 11:00 a.m., the stock rose 10.01% to 85.87 yuan and closed the daily limit. As of the closing, it rose 7.65% to close at 84.03 yuan, a weekly increase of 5.43%.
The industry believes that this change is closely related to the news. On the morning of the 25th, Guangzhou Kingmed Diagnostics Group Co.Ltd(603882) it was reported that the fifth wave of epidemic in Hong Kong was coming. As of 12:00 pm on the 24th, more than 81000 new cases had been confirmed, accounting for 86% of the total cases Guangzhou Kingmed Diagnostics Group Co.Ltd(603882) provided a group of five cabin in one “Falcon” hard film laboratory, which was officially put into use in Kowloon today, with a daily nucleic acid detection capacity of 80000 tubes. At present, the two laboratories in Hong Kong Jinyu and the “Falcon” hard film laboratory mainly undertake tasks including the Hong Kong Hospital Authority, the Department of health, the International Airport, the compulsory quarantine Hotel, a number of community testing centers, nearly 20 mobile sampling points and emergency testing in enclosed areas.
The company is a medical diagnosis information integration service provider with the outsourcing business of third-party medical examination and pathological diagnosis as the core Guangzhou Kingmed Diagnostics Group Co.Ltd(603882) 2021 third quarter report showed that the company’s main revenue was 8.617 billion yuan, up 47.87% year-on-year; The net profit attributable to the parent company was 1.672 billion yuan, a year-on-year increase of 58.52%; Deduct non net profit of 1.648 billion yuan, an increase of 61.62% year-on-year; In the third quarter of 2021, the company’s main revenue in a single quarter was 3.162 billion yuan, a year-on-year increase of 34.39%; The net profit attributable to the parent company in a single quarter was 613 million yuan, a year-on-year increase of 22.84%; The non net profit deducted in a single quarter was 619 million yuan, a year-on-year increase of 28.36%; The debt ratio is 40.28%, the investment income is -5.5849 million yuan, the financial expense is 7.77 million yuan, and the gross profit margin is 46.63%.
In terms of market value list, Shanghai Pharmaceuticals Holding Co.Ltd(601607) market value continued to decline by 693 million yuan this week. The market value of the stock shrank for three consecutive weeks, with a weekly decline of 1.92%. On February 25, Shanghai Pharmaceuticals Holding Co.Ltd(601607) obtained 638500 additional shares from Shanghai Stock connect, with the latest shareholding of 61036600 shares, accounting for 3.17% of the total A-share capital of the company.
On February 25, Shanghai Pharmaceuticals Holding Co.Ltd(601607) said on the investor interaction platform that the company’s industrial business was in good condition and its operating cash flow was stable. By the end of the third quarter of 2021, the company’s overall R & D investment was 1.715 billion, accounting for 9.12% of the sales revenue of the industrial sector. In the future, as more and more varieties in the company’s innovative drug pipeline enter registered clinical trials, the company expects the overall R & D investment to continue to grow.
It is worth noting that according to the disclosure of the board secretary, the company has announced that after the completion of Yunnan Baiyao Group Co.Ltd(000538) non-public private placement, the annual cash dividend ratio will be increased by no less than 40%. It is reported that on the evening of May 11, 2021, Shanghai Pharmaceuticals Holding Co.Ltd(601607) announced that Yunnan Baiyao Group Co.Ltd(000538) subscribed RMB 11.229 billion and joined Shanghai Pharmaceuticals Holding Co.Ltd(601607) as a strategic investor. After the transaction is completed, Yunnan Baiyao Group Co.Ltd(000538) will be able to nominate one candidate for executive director, one candidate for non-executive director and one candidate for supervisor. On the second day of the announcement of the news, Shanghai Pharmaceuticals Holding Co.Ltd(601607) opened lower, with the largest decline of more than 8%. More small and medium-sized investors made remarks accusing Shanghai Pharmaceuticals Holding Co.Ltd(601607) of ignoring the rights and interests of minority shareholders.
Shanghai Pharmaceuticals Holding Co.Ltd(601607) business mainly includes pharmaceutical industry and pharmaceutical commerce. Pharmaceutical business can be subdivided into pharmaceutical distribution business and pharmaceutical retail business. According to its third quarterly report of 2021, the company achieved an operating revenue of 160973 billion yuan from January to September 2021, with a year-on-year increase of 14.72%. The net profit attributable to shareholders of listed companies was 4.484 billion yuan, with a year-on-year increase of 24.49%, and the earnings per share was 1.5800 yuan.
At the same time, it also disclosed the phased progress made by nearly 10 innovative drug management lines. I036 obtained phase II clinical approval in April this year and has started the clinical study of Ewing’s sarcoma; I001-A added new indications for diabetic nephropathy in April and submitted a IND application. At the end of July, it had received notice of clinical trial, and was expected to start the II phase clinical trial in China. The indications of PD1 monoclonal antibody (BCD-100) for cervical cancer and non-small cell lung cancer have obtained phase III clinical approval respectively, and patients will be enrolled soon.
